Arrowhead Pharmaceuticals

ARWR

Last Price
06/16/26, 09:30 AM
 EDT
$
76.55
(
-0.8
%)
(
+
-0.8
%)
Margin of Safety
+
-63.1
%
Modeled Fair Value
$
28.27
Allocation Group
Future Compounder
Modeled Fair Value
$3.871 billion
Allocation Tier
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
An icon graphic of Gouldy the Finch.
#protectYourAssets

Solt DB will launch asset deep dives for all companies in the coverage ecosystem by the end of 2026. These will seamlessly integrate into company-specific financial models, allowing members to determine a company's fair value when specific assets are included or excluded.

Want me to prioritize a specific company or asset? Let me know on Discord or through the contact page.

Last Refined

August 14, 2025
The current model INCLUDES the following assets and assumptions:
The current model is based on operating metrics, including:
  • Component A: Plozasiran approval in familial chylomicronemia syndrome (FCS) in November 2025
  • Component B: Risk-weighted valuation contributions from plozasiran in SHASTA-3, SHASTA-4, and MUIR-3
The current model EXCLUDES the following assets:
  • Complement-mediated disease assets ARO-C3 and ARO-CFB (phase 2 ready)
  • Zodasiran in homozygous familial hypercholesteremia (HoFH) (phase 3)
  • ARO-INHBE and ARO-ALK7 obesity assets
  • ARO-DIMER-PA in mixed hyperlipidemia (phase 1 ready)
  • ARO-MAPT in Alzheimer's disease (phase 1/2 ready)
  • Plozasiran in SHASTA-5 (label expansion: acute pancreatitis in sHTG) and CAPITAN studies (label expansion: atherosclerotic cardiovascular disease (ASCVD) risk reduction)
  • ARO-RAGE in inflammatory lung diseases (phase 1/2)
  • ARO-PNPLA3 in a subset of metabolic-associated steatohepatitis (MASH) (phase 1)
  • Fazirsiran in alpha-1 antitrypsin (A1AT) liver disease (phase 3, partnered with Takeda)
  • ARO-SNCA in synucleinopathies such as Parkinson's disease (phase 1 ready, licensed to Novartis)
  • Olpasiran in atherosclerotic cardiovascular disease (ASCVD) (phase 3, licensed to Amgen)

SEC Filings